SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 1,200 shares, a drop of 57.1% from the January 31st total of 2,800 shares. Based on an average trading volume of 32,600 shares, the short-interest ratio is presently 0.0 days.

SAB Biotherapeutics Stock Performance

Shares of SABSW traded up $0.00 during midday trading on Friday, hitting $0.03. The company had a trading volume of 1,352 shares, compared to its average volume of 40,286. The company’s 50-day simple moving average is $0.07 and its 200-day simple moving average is $0.05. SAB Biotherapeutics has a 1 year low of $0.01 and a 1 year high of $0.18.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.